Pfizer (NYSE: PFE) director granted 7,686 phantom stock units as deferred pay

Rhea-AI Filing Summary

Gottlieb Scott reported acquisition or exercise transactions in this Form 4 filing.

Pfizer director Scott Gottlieb received a new grant of phantom stock units as part of his board compensation. On this Form 4, he was awarded 7,686.539 phantom stock units tied to Pfizer common stock at a reference value of $26.67 per unit, bringing his total phantom stock holdings to 57,001.814 units.

According to the footnotes, each unit represents one phantom share of common stock and was granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director compensation that will be settled in cash or common stock, at his election, after he retires from the Board of Directors, making this a non‑market, compensation-related transaction.

Insights

Equity compensation analyst

Routine deferred compensation grant in phantom stock units for a Pfizer director.

Pfizer director Scott Gottlieb received 7,686.539 phantom stock units, bringing his total phantom units to 57,001.814. The units are tied to Pfizer common stock value but are part of a deferred compensation arrangement rather than an open-market purchase.

The grant was made under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. The units will be settled in cash or common stock, at his election, after he leaves the Board. This is a standard, compensation-related award with limited informational value about his near-term view of Pfizer’s stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gottlieb Scott

Role null

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units	7,686.539	$26.67	$205K

Holdings After Transaction: Phantom Stock Units — 57,001.814 shares (Direct, null)

Footnotes (1)

1. Each unit represents one phantom share of common stock. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

Key Figures

Phantom stock units granted: 7,686.539 units Reference price per unit: $26.67 per unit Total phantom units after grant: 57,001.814 units +1 more

4 metrics

Phantom stock units granted 7,686.539 units Grant of phantom stock units on April 23, 2026

Reference price per unit $26.67 per unit Value used for the phantom stock unit grant

Total phantom units after grant 57,001.814 units Scott Gottlieb’s phantom stock holdings following the transaction

Underlying common stock equivalent 7,686.539 shares Each phantom stock unit represents one phantom share of common stock

Key Terms

Phantom Stock Units, Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, deferred director's compensation

3 terms

Phantom Stock Units financial

"Each unit represents one phantom share of common stock."

Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.

Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors financial

"Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors."

deferred director's compensation financial

"These units represent deferred director's compensation that are settled in cash or common stock at the director's election."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gottlieb Scott

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NEW YORK 10001-2192

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Units	(1)	04/23/2026		A		7,686.539(2)		(3)	(3)	Common Stock	7,686.539	$26.67	57,001.814	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.

3. These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors.

	/s/ Shanice A. Reid, by power of atty., for Scott Gottlieb	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pfizer (PFE) director Scott Gottlieb report in this Form 4 filing?

Scott Gottlieb reported receiving 7,686.539 phantom stock units tied to Pfizer common stock. This award increased his total phantom stock holdings to 57,001.814 units and reflects deferred board compensation rather than an open-market stock purchase or sale.

Are Scott Gottlieb’s Pfizer (PFE) phantom stock units an open-market stock purchase?

No. The 7,686.539 phantom stock units are a deferred compensation grant, not an open-market purchase. They were awarded under Pfizer’s Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors and represent bookkeeping units tied to Pfizer’s common stock value.

How and when will Scott Gottlieb’s Pfizer (PFE) phantom stock units be settled?

The phantom stock units will be settled after Scott Gottlieb retires from Pfizer’s Board of Directors. At that time, he may elect to receive settlement in cash or in Pfizer common stock, as specified in the deferred compensation plan footnotes.

What plan governs the Pfizer (PFE) phantom stock units granted to Scott Gottlieb?

The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. This plan awards phantom stock units as deferred director compensation, with each unit representing one phantom share of Pfizer common stock.

How many Pfizer (PFE) phantom stock units does Scott Gottlieb hold after this grant?

Following the reported grant, Scott Gottlieb holds a total of 57,001.814 phantom stock units. Each unit represents one phantom share of Pfizer common stock under the company’s deferred compensation plan for non-employee directors, to be settled after his board service ends.

What is the reference price for Scott Gottlieb’s new Pfizer (PFE) phantom stock units?

The 7,686.539 phantom stock units were recorded at a reference value of $26.67 per unit. This price is used for the grant entry and accounting purposes and does not represent an open-market trade by Scott Gottlieb in Pfizer shares.